Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin

Rheumatology (Oxford). 2021 Jul 1;60(7):e250-e251. doi: 10.1093/rheumatology/keab114.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Juvenile / genetics
  • Child
  • Cyclosporine / therapeutic use
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Methotrexate / therapeutic use
  • NF-KappaB Inhibitor alpha / genetics
  • Piperidines / therapeutic use
  • Pyrimidines / therapeutic use
  • Severity of Illness Index
  • Sirolimus / therapeutic use*
  • Treatment Failure
  • Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Glucocorticoids
  • Immunosuppressive Agents
  • NFKBIA protein, human
  • Piperidines
  • Pyrimidines
  • Tumor Necrosis Factor Inhibitors
  • NF-KappaB Inhibitor alpha
  • canakinumab
  • Cyclosporine
  • tofacitinib
  • tocilizumab
  • Sirolimus
  • Methotrexate